Gallium-68-PSMA-PET/CT Outperforms Radioiodine Scintigraphy and FDG–PET/CT in a Prospective Series of 10 Patients with Metastasized Differentiated Thyroid Cancer

Abstract

Clinical ThyroidologyVol. 30, No. 8 SummariesGallium-68-PSMA-PET/CT Outperforms Radioiodine Scintigraphy and FDG–PET/CT in a Prospective Series of 10 Patients with Metastasized Differentiated Thyroid CancerMartin BiermannMartin BiermannSearch for more papers by this authorPublished Online:1 Aug 2018https://doi.org/10.1089/ct.2018;30.388-390AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetailsCited byNew PET Tracer [68Ga]FAPI-004 Outperforms [18F] FDG in a Series of 34 Patients with Recurrent Differentiated Thyroid Cancer Martin Biermann6 July 2022 | Clinical Thyroidology, Vol. 34, No. 7Lesional Uptake of the Hypoxia Imaging Agent [18F] FAZA on PET/CT Predicts Progression in Metastatic Differentiated Thyroid Cancer Tom Christian Holm Adamsen and Martin Biermann6 October 2020 | Clinical Thyroidology, Vol. 32, No. 10New Radiolabeled Proteins May Hold Promise for PET Imaging of Recurrent Differentiated Thyroid Cancer Martin Biermann10 July 2019 | Clinical Thyroidology, Vol. 31, No. 7Zirconium-89–Labeled Anti-Galectin-3 Antibodies Show Thyroid Cancer–Specific Uptake in Three Thyroid Cancer Cell Lines in an Orthotopic Mouse Model Martin Biermann and Hans Kristian Haugland18 December 2018 | Clinical Thyroidology, Vol. 30, No. 12 Volume 30Issue 8Aug 2018 InformationCopyright 2018 American Thyroid Association, Inc.To cite this article:Martin Biermann.Gallium-68-PSMA-PET/CT Outperforms Radioiodine Scintigraphy and FDG–PET/CT in a Prospective Series of 10 Patients with Metastasized Differentiated Thyroid Cancer.Clinical Thyroidology.Aug 2018.388-390.http://doi.org/10.1089/ct.2018;30.388-390Published in Volume: 30 Issue 8: August 1, 2018PDF download